로딩 중…
지수 로딩 중…
Inhibrx Biosciences, Inc.
INBX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$82.72+0.82%
2026-08-03
Financials
Valuation Metrics
Inhibrx Biosciences, Inc.'s Market Cap is $1.21B. At end of 2025 it was $1.22B. Ranked #2395 of 3,112 in US market (top 77%), #964 of 1,445 on NASDAQ (top 67%), #180 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.21B | US#2,395/3,112 Sec#180/269 |
| Revenue | $1M | US#2,961/3,112 Sec#199/269 |
| Net Income | $-130M | US—/3,112 Sec—/269 |
| Total Assets | $184M | US#2,991/3,112 Sec#251/269 |
| Net Assets | $69M | US#2,913/3,112 Sec#237/269 |
| Value | ||
| P/B | 17.70x | US#2,782/3,112 Sec#228/269 |
| P/S | 933.54x | US#2,951/3,112 Sec#198/269 |
| FCF Yield | -10.87% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -189.89% | US#2,909/3,112 Sec#236/269 |
| ROA | -70.77% | US#3,021/3,112 Sec#249/269 |
| Op. Margin | -9465.46% | US#2,957/3,112 Sec#196/269 |
| Revenue Growth | 550.00% | US#36/3,112 Sec#14/269 |
| Earnings Growth | -108.30% | US#2,099/3,112 Sec#67/269 |
| Financial Health | ||
| Debt Ratio | 299.02% | US#2,115/3,112 Sec#220/269 |
| Total Debt | $6M | US#2,835/3,112 Sec#212/269 |
| FCF | $-132M | US#2,651/3,112 Sec#178/269 |
| Cash | $162M | US#1,891/3,112 Sec#137/269 |
| Current Ratio | 6.46x | US#369/3,112 Sec#121/269 |
| Performance | ||
| 1Y Return | 282.96% | US#55/3,112 Sec#19/269 |
| 1M Return | -15.23% | US#2,822/3,112 Sec#204/269 |
| From 52W High | -46.73% | US#2,712/3,112 Sec#211/269 |
| 1Y MDD | -44.13% | US#2,166/3,112 Sec#162/269 |
| Trading | ||
| Volume | 134,172 shares | US#2,844/3,112 Sec#260/269 |
| Trading Value | $11M | US#2,288/3,112 Sec#181/269 |
| Per Share | ||
| EPS | $-9.04 | US—/3,112 Sec—/269 |
| BPS | $0.52 | US#2,677/3,112 Sec#217/269 |